Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$102.28 USD
-2.40 (-2.29%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $102.80 +0.52 (0.51%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$102.28 USD
-2.40 (-2.29%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $102.80 +0.52 (0.51%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Zacks News
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) due to the performance of its oncology business and product launches.
Envista (NVST) Gains From New Acquisitions Amid FX Woes
by Zacks Equity Research
Envista's (NVST) implant businesses in Europe perform well on the back of disciplined commercial execution.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) due to the performance of its dental business.
Where Might 2024 Investors Harvest Returns?
by John Blank
One source for those answers: Chief Investment Officers (CIOs).
Humana's (HUM) CenterWell Unit Plans to Expand in Tennessee
by Zacks Equity Research
Humana's (HUM) CenterWell business is likely to benefit from its promising plans to expand across middle Tennessee this year.
Zimmer Biomet (ZBH) Gains From Procedure Recovery, New Launches
by Zacks Equity Research
Zimmer Biomet (ZBH) is encouraged about the early positive impact of the Hip Insight launch.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors continue to remain optimistic about National Vision (EYE) due to the expansion of stores and new investments for the improved optometric experience.
Why You Should Retain Walgreens Boots (WBA) Stock for Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) on a strong focus on strategic priorities.
Here's Why Investors Should Retain Phibro (PAHC) for Now
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) diversified offerings and booming vaccine business.
Here's Why Investors Should Retain SmileDirectClub (SDC) Now
by Zacks Equity Research
Meaningful innovations and strategic alliances boost investors' confidence in SmileDirectClub (SDC).
Strength Seen in Zimmer (ZBH): Can Its 3.8% Jump Turn into More Strength?
by Zacks Equity Research
Zimmer (ZBH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Here's Why You Should Retain Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC) on the impressive performance of the Surgical and Vision Care segments.
The FOMC, ECB, and BoJ: Global Week Ahead
by John Blank
Key risk market moments in the Global Week Ahead? They center on major central banks, with the U.S. Fed, the European Central Bank (ECB) and the Bank of Japan (BoJ) meeting.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.
Syneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes
by Zacks Equity Research
Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.
LabCorp (LH) Provides Update on Planned Spinoff of Fortrea
by Zacks Equity Research
After separation from LabCorp (LH), Fortrea is set to operate as a global contract research organization that offers comprehensive drug and medical device development services.
Here's Why Investors Should Retain Thermo Fisher (TMO) Stock
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher's (TMO) continued strength across its end markets and the the execution of the growth strategy.
Here's Why You Should Invest in IDEXX (IDXX) Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX) on the strength of the Companion Animal Group business.
Here's Why You Should Invest in Edward Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business performance and its strategies to accelerate growth.
Zimmer (ZBH) Down 8.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on the robust performances of the Neurosurgery and Cardiovascular portfolios.
Down -8.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Zimmer (ZBH)
by Zacks Equity Research
Zimmer (ZBH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why You Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.
ZBH vs. RMD: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ZBH vs. RMD: Which Stock Is the Better Value Option?